KeyCorp Analysts Lift Earnings Estimates for Iqvia Holdings Inc (IQV)

Iqvia Holdings Inc (NYSE:IQV) – Analysts at KeyCorp boosted their Q1 2018 earnings per share (EPS) estimates for Iqvia in a research note issued on Wednesday. KeyCorp analyst D. Hooker now forecasts that the medical research company will post earnings of $1.33 per share for the quarter, up from their prior forecast of $1.22. KeyCorp currently has a “Sector Weight” rating and a $100.00 price target on the stock. KeyCorp also issued estimates for Iqvia’s Q2 2018 earnings at $1.33 EPS, Q3 2018 earnings at $1.35 EPS, Q4 2018 earnings at $1.45 EPS, FY2018 earnings at $5.47 EPS and FY2019 earnings at $6.11 EPS.

A number of other analysts also recently weighed in on IQV. Zacks Investment Research downgraded Iqvia from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. Mizuho set a $97.00 price objective on Iqvia and gave the company a “hold” rating in a report on Wednesday, January 24th. SunTrust Banks restated a “hold” rating and issued a $110.00 price objective on shares of Iqvia in a report on Monday, January 22nd. Stifel Nicolaus upgraded Iqvia from a “hold” rating to a “buy” rating and increased their price target for the stock from $92.00 to $128.00 in a report on Friday, October 27th. Finally, TheStreet upgraded Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $109.71.

Shares of Iqvia (NYSE:IQV) opened at $104.68 on Thursday. The firm has a market capitalization of $20,811.27, a price-to-earnings ratio of 360.98, a P/E/G ratio of 1.36 and a beta of 0.61. Iqvia has a 1-year low of $75.94 and a 1-year high of $110.67. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.06. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.14 billion. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. Iqvia’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 earnings per share.

In other news, insider Ari Bousbib sold 46,080 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $101.79, for a total value of $4,690,483.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $764,776,314.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,727,078 shares of company stock valued at $890,124,079. Company insiders own 6.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Winslow Evans & Crocker Inc. acquired a new stake in shares of Iqvia in the 4th quarter valued at about $123,000. Focused Wealth Management Inc acquired a new stake in shares of Iqvia in the 4th quarter valued at about $166,000. Valeo Financial Advisors LLC acquired a new stake in shares of Iqvia in the 4th quarter valued at about $170,000. IFP Advisors Inc acquired a new stake in shares of Iqvia in the 4th quarter valued at about $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Iqvia in the 4th quarter valued at about $209,000. Institutional investors own 95.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “KeyCorp Analysts Lift Earnings Estimates for Iqvia Holdings Inc (IQV)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/15/keycorp-analysts-lift-earnings-estimates-for-iqvia-holdings-inc-iqv.html.

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply